Resources from the same session
1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
Presenter: Martin Voss
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1884MO - Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
Presenter: Roberto Iacovelli
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast